|
Market Closed -
Sao Paulo
02:23:48 12/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 93.24 BRL | +15.54% |
|
-0.58% | +41.36% |
| 07:30pm | Amgen's Sjogren's drug cuts disease activity in trial | RE |
| 07:26pm | Amgen Potential Autoimmune Drug Meets Primary Endpoint in Late-Stage Study | MT |
| Market Cap | 25TCr 1,40000Cr 23TCr 21TCr 19TCr 36TCr 23,60200Cr 37TCr 2,51100Cr 1,00100Cr 12,64100Cr 94TCr 92TCr 40,22600Cr | P/E 2026 * |
24x | P/E 2027 * | 22.9x |
|---|---|---|---|---|---|
| Enterprise Value | 29TCr 1,61900Cr 26TCr 24TCr 22TCr 41TCr 27,29400Cr 42TCr 2,90400Cr 1,15700Cr 14,61800Cr 1,09200Cr 1,06900Cr 46,51800Cr | EV / Sales 2026 * |
7.37x | EV / Sales 2027 * | 6.91x |
| Free-Float |
99.77% | Yield 2026 * |
2.17% | Yield 2027 * | 2.29% |
Last Transcript: Amgen Inc.
| 1 day | +15.54% | ||
| 1 week | -0.58% | ||
| Current month | +2.27% | ||
| 1 month | +25.32% | ||
| 3 months | +21.55% | ||
| 6 months | +62.52% | ||
| Current year | +41.36% |
| 1 week | 88.18 |  | 94.72 |
| 1 month | 73.99 | | 94.72 |
| Current year | 48.4 | | 94.72 |
| 1 year | 48.4 | | 94.72 |
| 3 years | 45.12 | | 94.72 |
| 5 years | 37.52 | | 94.72 |
| 10 years | 17.15 | | 94.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
| Director of Finance/CFO | 62 | 13/05/2010 | |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +15.54% | -0.58% | - | - | 25TCr | |
| +0.35% | +1.36% | +45.38% | +134.58% | 1,27600Cr | |
| -0.13% | +1.48% | +44.67% | +89.94% | 68TCr | |
| +0.37% | +0.05% | +31.00% | +112.77% | 52TCr | |
| +0.02% | +2.79% | +44.10% | +69.76% | 39TCr | |
| -0.59% | -2.11% | +61.83% | +43.63% | 36TCr | |
| -1.29% | +0.94% | +29.88% | +58.29% | 31TCr | |
| +0.09% | +0.99% | +5.87% | +37.72% | 29TCr | |
| +0.62% | -2.17% | +38.31% | +75.53% | 25TCr | |
| -0.67% | -2.72% | +38.49% | +126.52% | 21TCr | |
| Average | +1.55% | +2.34% | +37.73% | +83.19% | 48TCr | |
| Weighted average by Cap. | +0.93% | +2.51% | +40.29% | +95.42% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.95TCr 22TCr 3.56TCr 3.29TCr 2.97TCr 5.62TCr 3,70200Cr 5.76TCr 39TCr 16TCr 1,98300Cr 15TCr 14TCr 6,31000Cr | 4.13TCr 23TCr 3.72TCr 3.44TCr 3.11TCr 5.88TCr 3,87300Cr 6.03TCr 41TCr 16TCr 2,07400Cr 15TCr 15TCr 6,60000Cr |
| Net income | 1.05TCr 5.85TCr 948.25Cr 876.06Cr 791.97Cr 1.5TCr 99TCr 1.54TCr 10TCr 4.18TCr 53TCr 3.95TCr 3.86TCr 1,68200Cr | 1.1TCr 6.14TCr 993.89Cr 918.24Cr 830.09Cr 1.57TCr 1,03400Cr 1.61TCr 11TCr 4.39TCr 55TCr 4.14TCr 4.05TCr 1,76300Cr |
| Net Debt | 3.94TCr 22TCr 3.55TCr 3.28TCr 2.96TCr 5.61TCr 3,69200Cr 5.74TCr 39TCr 16TCr 1,97700Cr 15TCr 14TCr 6,29200Cr | 3.38TCr 19TCr 3.05TCr 2.81TCr 2.54TCr 4.81TCr 3,17000Cr 4.93TCr 34TCr 13TCr 1,69800Cr 13TCr 12TCr 5,40300Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | R$93.24 | +15.54% | 5,855 |
| 10/26/10 | R$93.16 | +1.38% | 6 |
| 09/26/09 | R$91.89 | +0.89% | 32 |
| 06/26/06 | R$91.08 | +0.20% | 270 |
| 05/26/05 | R$90.90 | -3.07% | 273 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
